1000 related articles for article (PubMed ID: 19821328)
21. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
22. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
23. Luteinising hormone releasing hormone (LHRH) agonists for the treatment of relapsed epithelial ovarian cancer.
Wuntakal R; Seshadri S; Montes A; Lane G
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD011322. PubMed ID: 27356090
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant hormonal therapy for premenopausal women with breast cancer.
Emens LA; Davidson NE
Clin Cancer Res; 2003 Jan; 9(1 Pt 2):486S-94S. PubMed ID: 12538505
[TBL] [Abstract][Full Text] [Related]
25. WITHDRAWN: Tamoxifen for early breast cancer.
Clarke MJ
Cochrane Database Syst Rev; 2008 Oct; 2008(4):CD000486. PubMed ID: 18843611
[TBL] [Abstract][Full Text] [Related]
26. Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
Jonat W
Br J Cancer; 1998 Sep; 78 Suppl 4(Suppl 4):5-8. PubMed ID: 9741781
[TBL] [Abstract][Full Text] [Related]
27. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
Loibl S; Turner NC; Ro J; Cristofanilli M; Iwata H; Im SA; Masuda N; Loi S; André F; Harbeck N; Verma S; Folkerd E; Puyana Theall K; Hoffman J; Zhang K; Bartlett CH; Dowsett M
Oncologist; 2017 Sep; 22(9):1028-1038. PubMed ID: 28652278
[TBL] [Abstract][Full Text] [Related]
28. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
29. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
30. Ovarian ablation for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2000; (3):CD000485. PubMed ID: 10908474
[TBL] [Abstract][Full Text] [Related]
31. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
[TBL] [Abstract][Full Text] [Related]
32. Ovarian ablation for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2000; (2):CD000485. PubMed ID: 10796722
[TBL] [Abstract][Full Text] [Related]
33. Adjuvant endocrine therapy for premenopausal women with breast cancer.
Puhalla S; Brufsky A; Davidson N
Breast; 2009 Oct; 18 Suppl 3(0 3):S122-30. PubMed ID: 19914530
[TBL] [Abstract][Full Text] [Related]
34. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.
Chen H; Xiao L; Li J; Cui L; Huang W
Cochrane Database Syst Rev; 2019 Mar; 3(3):CD008018. PubMed ID: 30827035
[TBL] [Abstract][Full Text] [Related]
35. Role of adjuvant endocrine therapy in early-stage breast cancer.
Muss HB
Semin Oncol; 2001 Aug; 28(4):313-21. PubMed ID: 11498825
[TBL] [Abstract][Full Text] [Related]
36. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
Thewes B; Meiser B; Duric VM; Stockler MR; Taylor A; Stuart-Harris R; Links M; Wilcken N; McLachlan SA; Phillips KA; Beith J; Boyle F; Friedlander ML
Lancet Oncol; 2005 Aug; 6(8):581-8. PubMed ID: 16054569
[TBL] [Abstract][Full Text] [Related]
37. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
Tancredi R; Furlanetto J; Loibl S
Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
[TBL] [Abstract][Full Text] [Related]
38. Tamoxifen for early breast cancer.
Early Breast Cancer Trialists' Collaborative Group
Cochrane Database Syst Rev; 2001; (1):CD000486. PubMed ID: 11279694
[TBL] [Abstract][Full Text] [Related]
39. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
